Last reviewed · How we verify

ocrelizumabu 200mg — Competitive Intelligence Brief

ocrelizumabu 200mg (ocrelizumabu 200mg) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: B-cell depleting monoclonal antibody; immunosuppressant. Area: Immunology.

discontinued B-cell depleting monoclonal antibody; immunosuppressant CD20 (cluster of differentiation 20) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ocrelizumabu 200mg (ocrelizumabu 200mg) — Chugai Pharmaceutical. Ocrelizumab selectively depletes CD20+ B lymphocytes to suppress autoimmune-mediated inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ocrelizumabu 200mg TARGET ocrelizumabu 200mg Chugai Pharmaceutical discontinued B-cell depleting monoclonal antibody; immunosuppressant CD20 (cluster of differentiation 20)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (B-cell depleting monoclonal antibody; immunosuppressant class)

  1. Chugai Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ocrelizumabu 200mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ocrelizumabu-200mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: